Assessing Semaglutide's Safety Profile Reveals Low Risk of NAION: Study
Written By : Dr. Garima Soni
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-08-08 21:30 GMT | Update On 2024-08-09 07:20 GMT
Advertisement
India: Association of semaglutide with the occurrence of nonarteritic anterior ischemic optic neuropathy (NAION) is very low, a current study reveals. This finding comes despite extensive media coverage on semaglutide’s potential link to NAION and its known association with retinopathy.
The study published in the Journal of The Association of Physicians of India indicated that NAION is not a known adverse drug reaction of semaglutide and the confirmed absolute risk of developing NAION from using semaglutide is probably very low.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.